摘要
沙利度胺因致畸作用撤出市场后又被发现在抗炎及免疫调节方面具有活性作用,并被美国FDA批准用于治疗麻风的并发症麻风结节性红斑。近年来其抗血管生成的作用又成为研究热点,2006年5月美国FDA批准其用于治疗多发性骨髓瘤,该药再次受到医学界的瞩目。文章以近几年来国内外有关沙利度胺研究的最新文献报道为基础,对沙利度胺在临床前及临床方面研究的最新进展进行了综述。
Although thalidomide was withdrawn from the European markets because of its teratogenic potential,FDA approved it for erythema nodosum eprosum lesions.And again thalidomide was approved at May of 2006 for the treatment of multiple myeloma owing to its anti-vascularization.This review summarizes the recent progress in both preclinical and clinical researches of thalidomide on the basis of related papers published in recent years.
出处
《中国肿瘤》
CAS
2011年第3期209-212,共4页
China Cancer
关键词
沙利度胺
抗血管生成
肿瘤
thalidomide
anti-vascularization
neoplasms
